PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Get Free Report) insider Deepika Jalota sold 7,218 shares of the stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $1.50, for a total transaction of $10,827.00. Following the sale, the insider now owns 118,283 shares in the company, valued at approximately $177,424.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
PMV Pharmaceuticals Stock Performance
Shares of NASDAQ PMVP opened at $1.49 on Friday. PMV Pharmaceuticals, Inc. has a 12-month low of $1.18 and a 12-month high of $6.98. The firm has a 50 day moving average of $1.56 and a 200 day moving average of $1.70.
PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.34) by $0.32. Analysts anticipate that PMV Pharmaceuticals, Inc. will post -1.05 earnings per share for the current year.
Analyst Upgrades and Downgrades
War on Elon Escalates…
From Porter & Company | Ad
Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades.
By doing so he has put himself in the crosshairs of an ideological war with the global elites.
And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
Click here to learn how you can benefit from its widespread distribution.
Separately, HC Wainwright reiterated a "buy" rating and issued a $5.00 price target on shares of PMV Pharmaceuticals in a research note on Tuesday, August 20th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $5.75.
Read Our Latest Analysis on PMV Pharmaceuticals
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of PMV Pharmaceuticals during the 2nd quarter valued at $101,000. Cubist Systematic Strategies LLC raised its holdings in PMV Pharmaceuticals by 570.8% during the second quarter. Cubist Systematic Strategies LLC now owns 69,867 shares of the company's stock valued at $113,000 after acquiring an additional 59,452 shares during the period. Evoke Wealth LLC purchased a new position in shares of PMV Pharmaceuticals in the second quarter valued at about $102,000. Assenagon Asset Management S.A. boosted its stake in shares of PMV Pharmaceuticals by 267.2% in the second quarter. Assenagon Asset Management S.A. now owns 260,028 shares of the company's stock worth $421,000 after acquiring an additional 189,214 shares during the period. Finally, Opaleye Management Inc. purchased a new stake in shares of PMV Pharmaceuticals during the first quarter worth about $802,000. Institutional investors own 90.20% of the company's stock.
PMV Pharmaceuticals Company Profile
(
Get Free Report)
PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
